Trial Profile
Early FDG PET/CT Imaging as a Measure of Response in Patients With Melanoma on Pembrolizumab
Status:
Discontinued
Phase of Trial:
Phase 0
Latest Information Update: 31 Mar 2023
Price :
$35
*
At a glance
- Drugs Pembrolizumab (Primary)
- Indications Malignant melanoma
- Focus Therapeutic Use
- 19 Jul 2021 Status changed from recruiting to discontinued.
- 01 Apr 2016 New trial record